Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
medroxyprogesterone acetate + estradiol + folic acid
- Development stage
- Unknown
- Lead developer
- Valdecasas
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
Dialeli AF is a combination oral medication developed and marketed by Laboratorios Valdecasas, primarily in Mexico. It consists of medroxyprogesterone acetate (a synthetic progestin), estradiol (a naturally occurring estrogen), and folic acid (vitamin B9). The product is indicated for hormone replacement therapy (HRT) to alleviate symptoms of menopause and for the treatment of certain menstrual irregularities. Medroxyprogesterone acetate acts as an agonist at the progesterone receptor, providing progestogenic activity that helps protect the endometrium, while estradiol acts as an agonist at estrogen receptors to supplement declining estrogen levels. The addition of folic acid (the "AF" in the name) provides nutritional support to prevent folate deficiency, which is particularly relevant for women of reproductive age or those undergoing hormonal shifts.
- Brand names
- Dialeli AF
- Other names
- medroxyprogesterone acetate + estradiol + folic acidDialeli AF
02
Targets
PR (Progesterone receptor)ESR1 (ERα)GR (Glucocorticoid receptor)ESR2 (ERβ)AR (Adrenergic receptors)
Beyond the preview
Go deeper on medroxyprogesterone acetate + estradiol + folic acid.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on medroxyprogesterone acetate + estradiol + folic acid.